RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $260 to $321.
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $260 to $321.